MUC1 and neoplasm: The administration of DCs loaded with MUC1-derived peptide, alone or in combination with other tumor-specific antigens, has been tested in several clinical trials for patients with refractory NSCLC [235], pancreatic cancer [236,237,238], biliary cancer [238], and castration-resistant prostate cancer (CRPC) [239].